Jet Generici will give the firm access to a product portfolio, a pipeline of registration applications, and a sales and marketing organization.
Dr. Reddy’s acquired Jet Generici, a company engaged in the sale of generic finished dosages in Italy. The deal was completed by Reddy Pharma Italia, Dr. Reddy’s subsidiary.
This represents Dr. Reddy’s second one this week; on April 1, a part of Dow Pharma’s small molecule business was bought. Jet Generici will provide access to an essential product portfolio, a pipeline of registration applications, and a sales and marketing organization.
“Dr. Reddy’s has taken a significant step forward by establishing its business in the third largest pharmaceutical market in Europe,” note VS Vasudevan, president and head of European operations for Dr. Reddy’s. “The acquisition has been well timed, since Dr. Reddy’s will be able to immediately supplement the Jet Generici portfolio via its own pipeline. We already have registration for one significant Dr. Reddy’s product, and a strong pipeline of registration applications.”
